clinical trial · NCT06955169
Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment
RTOG Foundation, Inc.·phase2·recruiting·n = 153
Intracranial Meningioma[177Lu]Lu-DOTATATEStandard of Care treatments
brief summary
This is an open-label, multicenter, randomized, phase 2 clinical study to evaluate the efficacy of \[177Lu\]Lu-DOTATATE in patients with progressive grade 1-3 intracranial meningioma.
started
Dec 24, 2025
primary completion
Aug 1, 2029
completion
Aug 1, 2030
last updated
Apr 21, 2026
detailed description
Study participants will be randomized by a 2:1 ratio to receive either \[177Lu\]Lu-DOTATATE or standard of care therapy as deemed appropriate by the local investigator. At time of progression, participants on the standard of care arm may cross-over to the \[177Lu\]Lu-DOTATATE alternative treatment arm.
official title
MOMENTUM-1: A Multicenter, Randomized, Open-Label, Phase II Study of [177LU]LU-DOTATATE in Adults With Progressive Intracranial Grade 1-3 Meningioma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol